The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties

• Published in: Journal of bone oncology 2021-12, Vol.31, p.100398, Article 100398
• Main Authors: Tattersall, Luke, Shah, Karan M., Lath, Darren L., Singh, Archana, Down, Jennifer M., De Marchi, Elena, Williamson, Alex, Di Virgilio, Francesco, Heymann, Dominique, Adinolfi, Elena, Fraser, William D., Green, Darrell, Lawson, Michelle A., Gartland, Alison
• Format: Article
• Language: English
• Subjects: ATP; Bone cancer; Cancer; Cell Behavior; Cellular Biology; Endocrinology and metabolism; Human health and pathology; Life Sciences; Osteosarcoma; P2RX7B; Pediatrics; Purinergic signalling; Research Paper; Rhumatology and musculoskeletal system; Tissues and Organs
• ISSN: 2212-1374; 2212-1366; 2212-1374
• DOI: 10.1016/j.jbo.2021.100398

•P2RX7B expression confers a survival advantage in TE85+P2RX7B and MNNG-HOS+P2RX7B OS cell lines.•P2RX7B expression reduced cell adhesion and activation promoted invasion and migration in vitro.•MNNG-HOS+P2RX7B tumours in vivo exhibited ectopic bone formation that A740003 reduced.•Expression of P2RX7B in primary tumour cells increased the propensity to metastasise to the lungs.•A novel gene axis, FN1/LOX/PDGFB/IGFBP3/BMP4 was downregulated in response to A740003. Osteosarcoma (OS) is the most common type of primary bone cancer affecting children and adolescents. OS has a high propensity to spread meaning the disease is often incurable and fatal. There have been no improvements in survival rates for decades. This highlights an urgent need for the development of novel therapeutic strategies. Here, we report in vitro and in vivo data that demonstrates the role of purinergic signalling, specifically, the B isoform of the purinergic receptor P2RX7 (P2RX7B), in OS progression and metastasis. TE85 and MNNG-HOS OS cells were transfected with P2RX7B. These cell lines were then characterised and assessed for proliferation, cell adhesion, migration and invasion in vitro. We used these cells to perform both paratibial and tail vein injected mouse studies where the primary tumour, bone and lungs were analysed. We used RNA-seq to identify responsive pathways relating to P2RX7B. Our data shows that P2RX7B expression confers a survival advantage in TE85 + P2RX7B and MNNG-HOS + P2RX7B human OS cell lines in vitro that is minimised following treatment with A740003, a specific P2RX7 antagonist. P2RX7B expression reduced cell adhesion and P2RX7B activation promoted invasion and migration in vitro, demonstrating a metastatic phenotype. Using an in vivo OS xenograft model, MNNG-HOS + P2RX7B tumours exhibited cancer-associated ectopic bone formation that was abrogated with A740003 treatment. A pro-metastatic phenotype was further demonstrated in vivo as expression of P2RX7B in primary tumour cells increased the propensity of tumour cells to metastasise to the lungs. RNA-seq identified a novel gene axis, FN1/LOX/PDGFB/IGFBP3/BMP4, downregulated in response to A740003 treatment. Our data illustrates a role for P2RX7B in OS tumour growth, progression and metastasis. We show that P2RX7B is a future therapeutic target in human OS.